metformine+glibenclamide/monot (500+2.5)mg/tab f.c.tab
lipha france - glibenclamide - ΕΠΙΚΑΛΥΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - (500+2.5)mg/tab
metformine+glibenclamide/monot (500+5)mg/tab f.c.tab
lipha france - glibenclamide - ΕΠΙΚΑΛΥΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - (500+5)mg/tab
metformine/b.i.farma 500mg/tab tab
b.i. farma a.e. - metformin - ΔΙΣΚΙΟ - 500mg/tab - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
metformin teva 1000mg/tab f.c.tab
teva pharma b.v., the netherlands - metformin - ΕΠΙΚΑΛΥΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ - 1000mg/tab - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
metformin accord 500mg film coated tablets
accord healthcare s.l.u (0000009808) moll de barcelona, edifici est s/n, planta 6, barcelona, 08039 - metformin hydrochloride - film coated tablets - 500mg - metformin hydrochloride (0001115704) 500mg
sitagliptin+metformin/grindeks f.c.tab (50+1000) mg/tab
jointstock company "grindeks", latvia (ΛΕΤΟΝΙΑ) krustpils 53,, lv-1057 riga - sitagliptin hydrochloride monohydrate; metformin hydrochloride - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - (50+1000) mg/tab - sitagliptin hydrochloride monohydrate 56,68mg; metformin hydrochloride 1.000mg - combinations of oral blood glucose lowering drugs
sitagliptin+metformin/grindeks f.c.tab (50+850) mg/tab
jointstock company "grindeks", latvia (ΛΕΤΟΝΙΑ) krustpils 53,, lv-1057 riga - sitagliptin hydrochloride monohydrate; metformin hydrochloride - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - (50+850) mg/tab - sitagliptin hydrochloride monohydrate 56,68mg; metformin hydrochloride 850mg - combinations of oral blood glucose lowering drugs
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - Σακχαρώδης διαβήτης τύπου 2 - Φάρμακα που χρησιμοποιούνται στον διαβήτη - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. θεραπεία τριπλού συνδυασμού) ως επιπρόσθετο στη δίαιτα και την άσκηση σε ασθενείς που δεν ελέγχονται επαρκώς με μέγιστη ανεκτή για αυτούς δόση μετφορμίνης και σουλφονυλουρίας. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
sitagliptin/metformin apc 100mg/1000mg modified-release tablet
apc instytut sp. z.o.o. (0000011610) ul. aleje jerozolimskie 146c, warsaw, mazowieckie, 02-305 - sitagliptin hydrochloride monohydrate; metformin hydrochloride - modified-release tablet - 100mg/1000mg - sitagliptin hydrochloride monohydrate (8000004805) 113,38mg; metformin hydrochloride (0001115704) 1000mg
sitagliptin/metformin apc 50mg/500mg modified-release tablet
apc instytut sp. z.o.o. (0000011610) ul. aleje jerozolimskie 146c, warsaw, mazowieckie, 02-305 - sitagliptin hydrochloride monohydrate; metformin hydrochloride - modified-release tablet - 50mg/500mg - sitagliptin hydrochloride monohydrate (8000004805) 56,69mg; metformin hydrochloride (0001115704) 500mg